Loading...

Posted on December 21, 2022 in binx blog

Lab-Equivalent Diagnostics in the Near-Patient Setting: How a First-Of-Its-Kind Platform Is Paving the Way for Women’s Health

December 21, 2022

Two of the most common sexually transmitted infections (STIs) in the US—chlamydia (CT) and gonorrhea (NG)— if left untreated can cause serious complications, including pelvic inflammatory disease and infertility in women. It is not uncommon, however, for an infection to be asymptomatic for women, and the Centers for Disease Control and Prevention (CDC) recommends routine testing for these STIs in all sexually active women under the age of 25 and all at-risk pregnant women.

Long wait times are a barrier to timely treatment

Despite this approach to early detection, long turnaround times associated with traditional testing pathways can stall initiation of treatment. Appropriate testing and treatment in pregnant women for STIs is an important way to prevent complications for the mother and baby. Early treatment during pregnancy will yield better health outcomes. Patients may wait up to 10 days for lab results, and patients may not return to the clinic for treatment if they do test positive for an infection.

From test to treatment in a single visit

Increasing access to routine testing for near-patient diagnostics is an important step forward for improving patient outcomes. Shortening the wait time for diagnostics from days to minutes, the binx io was the first platform to bring lab-equivalent performance to the point-of-care (POC) for CT/NG testing. With sample-to-answer results ready in about 30 minutes, a clinician can prescribe appropriate treatment before the patient leaves the setting—and help interrupt the transmission of these common STIs.

POC solutions poised for growth

The shift to a more patient-centric approach to health care is perhaps nowhere more evident than in the growth of POC testing. Bringing diagnostic technologies like the binx io to the near-patient settings for women’s health introduces the opportunity for an immediate healthcare interaction that traditional testing pathways to the central lab cannot provide. Perhaps that’s why the global market for point of care diagnostics is expected to grow at a rate of nearly 7% over the next 8 years, reaching a value of US $68.60 billion by 2030.

binx health aims to be part of that growth, building on our leading POC solution to broaden access and improve patient outcomes.